The centralized drug purchase is becoming more and more normal, and the pharmaceutical equipment industry is upgrading or accelerating

[pharmaceutical network market analysis] at present, with the normalization of new policies such as consistency evaluation, volume purchase and auxiliary drug restriction, the internal differentiation of the pharmaceutical industry is intensified, but the subdivision fields such as new drugs and APIs are created And chemicals, Chinese patent medicine and so on are still attracting a large number of investors In addition, under the aggravation of population aging and the implementation of medical insurance policy, the pharmaceutical industry is still favored by investors, which will be conducive to the growth of fixed asset investment in the industry of subdivisions, and the investment in related pharmaceutical equipment is expected to increase At the same time, with the promotion of policies such as centralized mining, the requirements of pharmaceutical enterprises for equipment production capacity have changed significantly, and the update pace of pharmaceutical equipment industry may be accelerated Pharmaceutical equipment (picture source: pharmaceutical network) segment equipment market still has room for development Taking API equipment as an example, the production technology and quality level of API in China have been improved continuously, which has developed from the stage of only producing low-end bulk APIs such as vitamins to the stage of mass production of more characteristic APIs At the same time, with the promotion of environmental protection, drug approval and Reform policies, the concentration of API industry in China has been increasing, without environmental protection requirements and Enterprises with production requirements are gradually eliminated, and excellent enterprises with compliant production are expected to get a golden development period In the process of continuous upgrading of API industry, API equipment is needed to help pharmaceutical enterprises to move forward towards the direction of environmental protection Therefore, relevant equipment enterprises are faced with the situation of both opportunities and challenges How to further reduce energy consumption and ensure green production has become the problem and direction that equipment enterprises need to explore It is reported that some enterprises have carried out long-term R & D and innovation to improve the performance of the equipment The system can save 50% of the energy consumption compared with the traditional equipment, which has brought good news for the energy conservation and environmental protection of pharmaceutical enterprises In addition, on January 2, 2020, the Ministry of industry and information technology and other four departments issued the notice on printing and distributing the guidance on promoting the green development of API industry The industrial structure of API will strive to be more reasonable In this context, the green and environmental API equipment is also expected to obtain opportunities The data shows that in 2018, the output of China's API and equipment accounted for 25.4% of the output of all pharmaceutical equipment products, among which some API equipment increased significantly, for example, extraction equipment increased by 33.7%, heat exchange equipment by 6.6% and drying equipment by 5.0% The industry believes that under the promotion of environmental protection and favorable policies, China's API equipment market still has great development space Update or accelerate the pace of pharmaceutical equipment industry In 2020, with the normalization of drug centralized procurement, the large quantity of medical insurance negotiation varieties and the successive listing of new products, the requirements of drug manufacturers for production capacity and product quality will change Pharmaceutical equipment with high automation, intelligence, continuity, efficiency, integration, traceability and other functions will become the demand of drug manufacturers, which will also promote the development of China's pharmaceutical industry The pharmaceutical equipment industry is gradually moving from low-end to medium and high-level In fact, from the point of view of the encouragement policies and market demands given by the state, in terms of policies, the state issues documents to encourage the development of advanced pharmaceutical equipment and technology; in terms of markets, pharmaceutical enterprises, especially the "4 + 7" bid winning enterprises, also need high-capacity and low-cost pharmaceutical equipment to solve the problems of market supply and cost control, which cannot be separated from the upgrading of pharmaceutical equipment It can be seen that the market penetration rate of domestic advanced pharmaceutical equipment is expected to continue to improve in the future, which will also be the goal that domestic pharmaceutical equipment enterprises need to strive for At present, in order to better solve various problems encountered in the pharmaceutical production process, some leading equipment enterprises in China have changed their roles from single equipment suppliers to overall solution suppliers, and can put forward practical solutions based on the actual needs of pharmaceutical enterprises For example, in view of the current capacity problem of the bid winning enterprises, the pharmaceutical machinery enterprises put forward the "4 + 7" centralized water supply overall solution Compared with the traditional multi effect distilled water machine, it covers a smaller area, produces better water quality, saves energy and reduces consumption significantly, and the water and steam production indexes of the whole system are far higher than those of the Pharmacopoeia Conclusion: the pharmaceutical equipment industry is a non cyclical industry In recent years, the overall growth of China's pharmaceutical industry is relatively stable In addition, the elimination rate of five-year pharmaceutical equipment ensures the necessity of pharmaceutical equipment upgrading With the normalization of new policies such as volume purchase, the pace of pharmaceutical equipment renewal may be further accelerated.